Phibro Animal Health Corporation

Healthcare · Drug Manufacturers - Specialty & Generic

33.90$ -0.5% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Phibro Animal Health Corporation (PAHC) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2026), "Revenue" came in at 1,518 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement PAHC
Line item	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Revenue	323	320	329	338	354	364	398	453	511	537	594	618	654	653	692	749	752	764	820	828	800	833	942	978	1,018	1,296	1,518
Cost of Revenue	250	250	247	249	265	293	307	342	390	408	440	472	490	474	484	512	513	516	553	563	543	562	657	680	705	896	1,006
Gross Profit	73	69	81	89	89	71	91	111	122	130	155	147	164	179	208	236	239	248	267	265	257	271	285	298	313	400	512
Research & Development	1.6	3.0	5.3	4.6	5.1	5.6	–	4.7	5.7	6.0	–	–	7.2	6.6	8.2	9.5	11	9.4	10.0	12	14	18	21	24	29	24	–
Selling, General & Administrative	59	64	71	63	63	67	68	76	81	85	102	105	115	122	144	149	153	150	168	181	188	197	206	226	260	289	313
Total Operating Expenses	58	64	71	63	46	67	68	90	92	88	102	105	115	122	144	149	153	150	168	181	188	197	206	226	260	289	313
Operating Income	16	5.4	11	26	44	4.4	23	21	29	41	53	41	49	57	64	88	86	98	99	73	69	75	79	72	53	110	198
Interest Expense	14	18	18	17	21	27	33	27	27	43	33	35	36	36	33	15	17	15	12	14	14	10	12	18	22	33	48
Pre-Tax Income	14	-12	-10	7.0	24	-21	-7.9	-6.3	1.9	-2.1	20	-7.9	13	18	6.3	79	77	81	88	72	56	66	72	54	11	68	137
Income Tax Expense	3.9	-0.4	15	9.8	7.8	2.1	5.2	0.4	2.6	3.4	3.8	5.0	6.1	-7.0	9.4	18	-6.0	16	23	17	22	12	23	21	8.5	20	38
Net Income	10	-15	-52	-18	13	-22	-13	-6.7	2.2	-8.3	42	-13	7.0	25	-3.1	60	83	65	65	55	34	54	49	33	2.4	48	100
EBITDA	12	-23	-42	-14	11	-29	-27	-23	-22	-48	13	43	66	73	61	115	117	124	126	113	102	110	117	106	69	147	236

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings